PharmaVision offers a comprehensive choice of high quality, insightful reports which identify key trends, future innovations, and growth opportunities. Our reports cover the life science arena including pharmaceuticals, healthcare, diagnostics, drug delivery, emerging R&D technologies and consumer nutrition.
2012 has arrived and with it Tevas announcement that Shlomo Yanai, President & CEO will retire in May 2012 to be succeeded by Dr. Jeremy Levin, former senior executive at BMS. This will represent a new phase in Tevas growth strategy as Dr Levin puts into practice his considerable expertise in optimizing R&D alliances and expanding the global footprint of this leading diversified pharmaceutical company. For more information read our featured report...
Chronic, non-healing wounds are a major problem in the West. Ageing, obesity and increasingly common underlying conditions, such as diabetes, are significant contributory factors and will remain pivotal drivers in the future growth of the wound care market. Malnutrition, particularly amongst elderly patients, is known to inhibit healing.
